Division of Colon and Rectal Surgery, Department of Surgery, NewYork-Presbyterian, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 8th Floor, New York, NY, 10032, USA.
Minimally Invasive Therapies Group, Medtronic, Inc, Boulder, CO, USA.
Surg Endosc. 2019 Jun;33(6):1959-1966. doi: 10.1007/s00464-018-6477-5. Epub 2018 Oct 17.
Opioids are a mainstay for postsurgical pain management, but have associated complications and costs, and contribute to the opioid epidemic. While efforts to reduce opioid use exist, little study has been done on opioid utilization and its impact across surgical approaches. Our goal was to evaluate the impact of opioid utilization on quality measures and costs after open and laparoscopic colorectal surgery.
The Premier database was reviewed for inpatient colorectal procedures from January 01, 2014, to September 30, 2015. Procedures were stratified into open and laparoscopic approaches, then "opioid" and "opioid-free" groups within each approach. Univariate analysis compared demographics, outcomes, and cost by opioid use and surgical approach. In the "opioid" groups, opioid consumption and duration were assessed across platforms. Multivariate regression analyzed the association between opioid use and surgical approach on costs and quality outcomes.
50,098 procedures were evaluated-40.4% laparoscopic and 59.6% open. 6.6% of laparoscopic and 5.3% of open cases were "opioid free." Across both approaches, patients over 65 were most likely opioid free, while the obese and cancer patients were most likely to use opioids. Length of stay was shorter, and post-discharge nursing needs and total costs were lower in the "opioid-free" group in both approaches (all p < 0.001). The median daily and total opioid consumption were lower with a laparoscopic approach (p < 0.001), which also had a shorter duration of use versus open cases (p < 0.001). Opioids were 20% more likely in open cases. Total costs were 16% greater with opioids and 24% greater in open surgery. Complications were 89% more likely in open surgery. Readmissions were increased by 14% with both opioid use and open surgery.
Opioid-free colorectal surgery results in improved outcomes, and laparoscopy further improves these results. Continued efforts to increase laparoscopy are key for reducing opioids and improving outcomes as we transition to value-based care.
阿片类药物是术后疼痛管理的主要药物,但存在相关并发症和成本,并且导致阿片类药物流行。虽然已经在努力减少阿片类药物的使用,但对手术方法之间阿片类药物的使用及其影响的研究很少。我们的目标是评估阿片类药物使用对开放式和腹腔镜结直肠手术后质量指标和成本的影响。
从 2014 年 1 月 1 日至 2015 年 9 月 30 日,对 Premier 数据库中接受住院结直肠手术的患者进行了回顾性分析。手术分为开放式和腹腔镜式,然后在每种手术方法内分为“阿片类药物”和“无阿片类药物”组。单变量分析比较了使用阿片类药物和手术方式的人口统计学、结果和成本。在“阿片类药物”组中,评估了各个平台上的阿片类药物消耗和持续时间。多变量回归分析了阿片类药物使用与手术方式对成本和质量结果的关联。
共评估了 50098 例手术,其中 40.4%为腹腔镜,59.6%为开放式。6.6%的腹腔镜手术和 5.3%的开放式手术为“无阿片类药物”。在这两种方法中,年龄在 65 岁以上的患者最有可能不使用阿片类药物,而肥胖和癌症患者最有可能使用阿片类药物。无阿片类药物组的住院时间较短,出院后护理需求和总费用在两种方法中均较低(均 p<0.001)。与开放式病例相比,腹腔镜方法的中位每日和总阿片类药物消耗量较低(p<0.001),使用时间也较短(p<0.001)。开放式病例中阿片类药物的使用可能性高 20%。使用阿片类药物的总成本增加了 16%,开放式手术的总成本增加了 24%。开放式手术并发症的可能性增加了 89%。使用阿片类药物和开放式手术的再入院率分别增加了 14%。
无阿片类药物的结直肠手术可改善结果,而腹腔镜手术则进一步改善了这些结果。随着我们向基于价值的护理模式过渡,继续努力增加腹腔镜手术的使用是减少阿片类药物和改善结果的关键。